180
Participants
Start Date
February 9, 2018
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Palbociclib
Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Placebo
Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Tamoxifen
Tamoxifen, 20mg, orally once daily (continuously)
Goserelin
For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
National Taiwan University Hospital, Taipei
National Cancer Center, Gyeonggi-do
Taipei Vetarans General Hospital, Taipei
Sun Yat-Sen Cancer Center, Taipei
Ajou University Hospital, Gyeonggi-do
National University Hospital, Singapore
National Cancer Centre Singapore, Singapore
Toranomon Hospital, Minato-Ku
Kanagawa Cancer Center, Yokohama
Chiba Cancer Center, Chiba
National Cancer Center Hospital East, Kashiwa
National Hospital Organization Osaka National Hospital, Osaka
Kindai University Hospital, Ōsaka-sayama
Hyogo Cancer Center, Akashi
National Hospital Organization Shikoku Cancer Center, Matsuyama
Kyusyu Cancer Center, Fukuoka
Aichi Cancer Center Hospital, Nagoya
National Hospital Organization Hokkaido Cancer Center, Sapporo
National Cancer Center Hospital, Tokyo
Seoul National University Bundang Hospital, Gyeonggi-do
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Severance Hospital, Yonsei University Health System, Soeul
Collaborators (1)
Pfizer
INDUSTRY
Korean Cancer Study Group
OTHER
National Cancer Center, Japan
OTHER_GOV